Be part of the knowledge.™

DARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure

Name: DARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
Uploaded: 2025-11-12T05:00:00+00:00
Description: In this video brief, Dr. Clyde W. Yancy presents the DARE‑AF randomized trial, which evaluates dapagliflozin in patients undergoing first-time catheter abl

Media Formats

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details

Presenters

Overview
In this video brief, Dr. Clyde W. Yancy presents the DARE‑AF randomized trial, which evaluates dapagliflozin in patients undergoing first-time catheter ablation for atrial fibrillation without diabetes or heart failure. Dr. Yancy discusses the rationale for SGLT2 inhibition in this context and reviews the potential clinical implications of the study results.
Provider(s)/Educational Partner(s)

Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.

Clyde W. Yancy, MD

Recommended

Details

Presenters

Overview
In this video brief, Dr. Clyde W. Yancy presents the DARE‑AF randomized trial, which evaluates dapagliflozin in patients undergoing first-time catheter ablation for atrial fibrillation without diabetes or heart failure. Dr. Yancy discusses the rationale for SGLT2 inhibition in this context and reviews the potential clinical implications of the study results.
Provider(s)/Educational Partner(s)

Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.

Clyde W. Yancy, MD

CME Learning Centers

CME/CE Topic Areas

Spotlight On:

Lifestyle

Trending Topics

DARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure

Provider(s)/Educational Partner(s)

Provider(s)/Educational Partner(s)

Program Chapters

Segment Chapters

Playlist:

Recommended

Transcript